There is no excerpt because this is a protected post.
HTA Council Preliminary Recommendation on Aflibercept, Ranibizumab, and Dexamethasone Implant for the Treatment of Retinal Diseases
As of 27 January 2026, the HTA Council has completed the evidence appraisal on the assessment of the following drugs for their respective indications, for possible government financing: The HTA Council hereby releases its preliminary recommendation on the said health technologies for stakeholder feedback and comments from 27 January to 10 February 2026. These health technologies were continue reading : HTA Council Preliminary Recommendation on Aflibercept, Ranibizumab, and Dexamethasone Implant for the Treatment of Retinal Diseases
HTA Council Preliminary Recommendation on Meningococcal Polysaccharide Groups A, C, W-135 And Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by 𝙉𝙚𝙞𝙨𝙨𝙚𝙧𝙞𝙖 𝙢𝙚𝙣𝙞𝙣𝙜𝙞𝙩𝙞𝙙𝙞𝙨 group A, C, W-135 and Y
Update as of 09 February 2026: Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Meningococcal Polysaccharide Groups A, C, W-135 And Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by 𝙉𝙚𝙞𝙨𝙨𝙚𝙧𝙞𝙖 𝙢𝙚𝙣𝙞𝙣𝙜𝙞𝙩𝙞𝙙𝙞𝙨 group A, C, W-135 and Y continue reading : HTA Council Preliminary Recommendation on Meningococcal Polysaccharide Groups A, C, W-135 And Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by 𝙉𝙚𝙞𝙨𝙨𝙚𝙧𝙞𝙖 𝙢𝙚𝙣𝙞𝙣𝙜𝙞𝙩𝙞𝙙𝙞𝙨 group A, C, W-135 and Y
HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)
As of 01 December 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg/10 mg capsule] for adults diagnosed with advanced continue reading : HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)
HTA Council Preliminary Recommendation on Thermal Ablation for the Treatment of Premalignant Lesions of the Cervix among Women 30 to 65 years old
As of 19 November 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Thermal Ablation for the treatment of premalignant lesions of the cervix among women 30 to 65 years old who are deemed eligible for ablation in accordance to the World Health Organization (WHO) screen-treat approach or screen-triage-treat continue reading : HTA Council Preliminary Recommendation on Thermal Ablation for the Treatment of Premalignant Lesions of the Cervix among Women 30 to 65 years old